Nestle Invests $43 Million in Maker of Disease-Battling Proteins

  • CEO of Health Science unit Behar also joins startup's board
  • Pronutria targets diseases caused by amino acid imbalances

Nestle SA, the world’s biggest food company, invested $43 million in Pronutria Biosciences, a U.S. developer of proteins that target neurological, muscle and liver diseases, its latest investment in a health startup.
Pronutria has a product in clinical testing to treat muscle-wasting diseases caused by imbalances in amino acids, Nestle said Tuesday in a statement. Greg Behar, chief executive officer of the Swiss firm’s Health Science unit, will join the board of the Cambridge, Massachusetts-based startup.
The U.S. company is engaged in “paradigm-changing science” to address unmet medical needs, Behar said in the statement.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.